2004
DOI: 10.1007/s00280-004-0847-5 View full text |Buy / Rent full text
|
|

Abstract: Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)-O,O'] platinum; Eloxatin) is a third-generation platinum compound with a 1,2-diaminocyclohexane (DACH) carrier ligand, which has a wide spectrum of anticancer activity in vitro systems and has displayed preclinical and clinical activity in a wide variety of tumors. To investigate its in vitro activity against head and neck cancer, we exposed two head and neck cancer cell lines to the compound, created a variant resistant to cisplatin to study … Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
1
0
4
0

Year Published

2007
2007
2022
2022

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

0
4
0
Order By: Relevance
“…Therefore, a combination of these two agents is attractive for evaluation in SCCHN. [19,20] In this study, two other patients with head and neck malignancies experienced objective response and stable disease, respectively. The results of this study also support observations of the previous phase I study of pemetrexed-oxaliplatin, which demonstrated stable disease in patients with head and neck cancer.…”
Section: Discussionmentioning
“…Oxaliplatin may be the most interesting of the additional drugs tested. Despite displaying little FANC genotype- and dose-dependent cell killing, oxaliplatin has shown little cross-resistance with cis -Pt in HNSCC cell lines (49) and displays the ability to potentiate anti-PD-1 immunotherapy in preclinical models (50). These differences may reflect a different mechanism of action for oxaliplatin versus other platinum-based therapeutics such as cis- and carbo-Pt and potential utility as a HNSCC therapeutic agent (51,52).…”
Section: Discussionmentioning
“…Oxaliplatin and carboplatin are platinum-containing compounds with a wide-spectrum anticancer effect and potent preclinical and clinical activity in a large variety of tumours. They are also a possible choice in the treatment of OSCC, although they are not widely used (30).…”
Section: Chemotherapymentioning
“…[15] A review of the literature indicates that (R,R)-diaminocyclohexane-bearing compounds is a family of effective anticancer agents. [16,17] There also exist a number of well-documented amino group-bearing compounds, which can interact with DNA [18] or RNA [19] as antibiotics. New evidence has accumulated which shows that polyamino-based compounds might be effective in binding to a particular region of DNA, and hence regulate mRNA expression in human breast cancer cells.…”
Section: Introductionmentioning